Purpose/Objective: There are a few reports of the radiotherapy for synchronous carcinomas in the head and neck (H&N) and esophagus. Purpose of this retrospective study is to analyze the results of definitive radiotherapy and find the possible prognostic factors.
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All India Institute of Medical Sciences, Radiation Oncology, New Delhi, India 2 All India Institute of Medical Sciences, Radiodiagnosis, New Delhi, India 3 All India Institute of Medical Sciences, Medical Physics, New Delhi, India 4 All India Institute of Medical Sciences, Medical Oncology, New Delhi, India Purpose/Objective: To evaluate the dose to carotid artery in patients treated with intensity modulated radiation therapy (IMRT) for oropharyngeal cancer. Materials and Methods: Ten patients with locally or regionally advanced oropharyngeal cancer were treated with IMRT. The primary tumour involvement was as follows: base of tongue (n=4), tonsil (n=2),vallecula (n=3), and soft palate (n=1). The TNM classification of the tumour was as follows: T2 (n=1), T3 (n=8), T4a (n=1), N0 (n=5), N1 (n=2), N2b (n=1), N2c(n=2), and M0 (n=10). The planning CECT scan was obtained at 3 mm slice thickness. The right and left common, internal, and external carotid arteries were contoured from the level of sterno-clavicular joint to the base of skull. The following dose schedule was prescribed for IMRT: 70 Gy in 35 fractions (2 Gy per fraction) to GTV with 0.5-1.0 cm margin (CTV1), 63 Gy in 35 fractions (1.8 Gy per fraction) to high-risk CTV2, and 56 Gy in 35 fractions (1.6 Gy per fraction) to the low-risk CTV3. A PTV margin of 5 mm was given to the respective CTV. The plan was normalized such that at least 95% of the volume of PTV1 to be covered by the 70 Gy isodose; no more than 20% of PTV1 to receive ≥77 Gy; and no more than 5% of PTV1 to receive ≥80.5 Gy. In addition, no more than 1% of any distinct PTV to receive ≤ 93% of the prescribed dose and no more than 1% of the tissue outside the PTV to receive ≥110% of the dose prescribed to PTV1. The treatment was delivered using 6 MV X-rays. Dose-volume histogram (DVH) was obtained for each of the 20 carotid arteries. Results: The median volume of the carotid artery was 6.2 cc (range, 4.5-8.7 cc). The median of the mean dose to carotid artery was 58.4 Gy (range, 53.3-64.3 Gy). The median of the maximum dose to carotid artery was 75.9 Gy (range, 61-79.1 Gy). The median and range of V40, V50, V60, and V70 were 5.7 cc (4.2-7.9 cc), 5.5 cc (4.1-7.8 cc), 3.8 cc (0.9-5.5 cc), and 1.2 cc (0.0-3.0 cc), respectively. With regard to the N0 cases, the median of mean and maximum dose to carotid artery was 58 Gy and 73.2 Gy respectively. The median of mean and maximum dose in N+ cases was 59.9 Gy and 77.3 Gy respectively. Conclusions: The dose heterogeneity in IMRT may contribute to increase in maximum dose to the carotid arteries. Long term clinical outcome may elucidate the risk of cerebrovascular events in patients treated with IMRT for oropharyngeal cancer.
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Cetuximab (Erbitux) plus radiotherapy versus concomitant Cisplatin plus radiotherapy within an NHS oncology unit C. Brammer 1 , D. Dawson 1 , S. Merrick 1 , P. Ramachandra 1 , C. Glaister 1 , M. Openshaw 1 1 New Cross Hospital Deanesly Centre, Radiation Oncology Department, Wolverhampton, United Kingdom Purpose/Objective: To compare the differences in resource utilisation between Cetuximab plus RT (EBRT) versus Cisplatin plus radiotherapy (CRT) taking in to account drug costs, clinical management and the costs of managing treatment related toxicity. Effects of treatment on quality of life, overall survival and local recurrence were also measured . Materials and Methods: 20 patients with stage 3 or 4 HNSCC were randomised between concomitant weekly Cetuximab or weekly Cisplatin plus XRT 70Gy in 35 fractions (10 Cetuximab, 10 Cisplatin). All drugs and hospital contacts were recorded to allow assessment of the health-economic impact of the management of toxicity additional to the initial cost of treatment. Data was collected for the acute phase, start of treatment to 6 weeks after completion of radiotherapy and late phase, from 6 weeks following completion of treatment to 6 months following completion of treatment. Quality of life questionnaires were completed at baseline, at end of radiotherapy , 6 weeks following completion of therapy and 6 months following completion of treatment. All patients have been followed up for greater than 24 months for survival and local recurrence rates. Biopsies have been retrospectively tested for p16 positivity by immunohistochemisty Results: Patients receiving Cisplatin required more intense management during the treatment and acute phase they were more likely to require overnight admission and required more laboratory and radiological investigation compared to those treatment with Cetuximab. Patients treated with Cisplatin also had more unplanned visits to hospital for management of the side effects of treatment. There was no significant difference between the two arm of the study for time spent with the head and neck CNS, Dietician or speech and language therapist. There were no differences in quality of life parameters between the 2 arms of the study although patients treatment with Cetuximab were significantly less likely to be using a feeding tube at 6 months. c 2 p= 0.04. While the study was not powered to investigate differences in survival or local recurrence rates there was a statistically significant increase in local recurrence in patients treated by Cetuximab in this study. log rank p=0.014 Conclusions: While the overall costs of drug treatment plus emergency admission are higher for Cetuximab when compared to Cisplatin terms patients undergoing Cisplatin and Radiotherapy require significantly more non routine intervention and care than patients receiving Cetuximab and Radiotherapy in this randomised study and this should be taken in to account when planned further trials. A study comparing cisplatin and Cetuximab to investigate quality of life and late functional effects of treatment could be viable within the NHS. Any future study should also be powered to investigate potential differences in overall survival and local recurrence rates Purpose/Objective: To report our initial clinical experience of Helical Tomotherapy (HT) in the treatment of locally advanced oropharynx and inoperable oral cavity carcinoma, in terms of response, acute and late toxicity rates. Materials and Methods: Between February 2008 and January 2011, 24 consecutive patients, 15 with oropharyngeal and 9 with oral squamous cell carcinoma were treated with exclusive radiotherapy or concomitant chemoradiotherapy. Simultaneous integrated boost (SIB) in 30 fractions scheme was prescribed to all patients, using Helical Tomotherapy. Patients treated with exclusive radiotherapy received a dose of 67.5 Gy in 2.25 Gy daily fractions for tumor and 63 Gy in 2.1
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